Immucell (ICCC) Receivables - Net (2010 - 2026)

Immucell (ICCC) has reported Receivables - Net for 17 consecutive years, with $2.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables - Net rose 21.79% year-over-year to $2.9 million; the trailing twelve-month figure through Jun 2026 stood at $2.9 million (up 21.79% YoY), and the FY2025 full-year result was $3.4 million, down 9.34% from the prior year.
• Receivables - Net improved to $2.9 million in Q2 2026 per ICCC's latest filing, from $2.6 million in the prior quarter.
• Across five years, Receivables - Net topped out at $3.3 million in Q1 2025 and bottomed at $42507.0 in Q4 2023.
• Historically, Receivables - Net has averaged $1.9 million across 5 years, with a median of $2.0 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Receivables - Net tumbled 97.58% in 2023, then surged 30.13% in 2024.
• Over 5 years, Receivables - Net stood at $1.8 million in 2022, then sank by 97.58% to $42507.0 in 2023, then rose by 22.56% to $52097.0 in 2024, then surged by 4803.86% to $2.6 million in 2025, then grew by 13.41% to $2.9 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $2.9 million, $2.6 million, and $2.4 million for Q2 2026, Q3 2025, and Q2 2025 respectively.